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ABSTRACT 
Gene expression consists of multiple strictly regulated steps, including transcription, RNA 
modification, splicing, messenger RNA (mRNA) transport, mRNA degradation, mRNA 
translation and protein degradation. mRNA translation, the most energy consuming step, 
plays a critical role in gene expression via global and selective control of protein synthesis. 
Translation is a complex process that is commonly divided into initiation, elongation and 
termination. Among these, translation initiation is widely acknowledged as the rate-limiting 
step for mRNA translation. The mammalian/mechanistic target of rapamycin (mTOR) 
pathway, as one important regulator of translation initiation, delivers vital signaling by 
phosphorylating eIF4E binding proteins (4E-BPs) thereby facilitating eIF4F complex 
formation which participates in eukaryotic cap dependent translation. Increased mTOR 
activity and dysregulation of translation have been observed in many diseases, such as cancer 
as well as immune and metabolic disorders. Sequence and structure features of the mRNA, 
the translational apparatus and trans-acting proteins facilitate or restrict translation regulation 
of an mRNA. Moreover, these factors can potentially alter the translational efficiency of an 
mRNA thereby impacting protein levels without changes in mRNA levels. Accordingly, a 
well-established technique to study translatomes, polysome profiling, separates efficiently 
translated mRNA from total mRNA into multiple fractions based on the number of ribosomes 
bound on the mRNA. Extraction of these fractions is a time consuming and laborious process, 
which makes polysome profiling inconvenient for large experiments or samples with low 
RNA amounts. Until now, these shortcomings have prevented assessments of translatomes in 
patient tissue samples. 
This thesis introduces an optimized non-linear sucrose gradient which consistently enriches 
the efficiently translated mRNA in merely one or two fractions, thus reducing sample 
handling 5-10 fold and saving time in the lab 10-20 fold. When combined with smart-seq2 
RNA sequencing, translatomes can be obtained from samples with low amount of RNA and 
small bio-banked tissues. mRNA yields and translatomes acquired from the optimized 
gradients resemble those obtained from the standard linear gradients. Thus, this optimized 
polysome-profiling technique expands the usage of the methodology to small tissue samples 
and primary cells in large study designs.  
Insulin sensitive mRNA translation has been observed in cancer cells derived from insulin 
insensitive organs, for instance breast. It is largely unknown that if this insulin sensitivity 
resembles that of cells from insulin sensitive organs or if cancer cells tailor a novel program. 
To this end, this thesis explored insulin’s effect on metabolomes and translatomes in human 
primary myotubes, human mammary epithelial cells immortalized with human telomerase 
(HMEC/hTERT) and the MCF7 breast cancer cells. The data indicates that MCF7 cells have 
developed pathological responses to insulin induction that differ from those observed in cells 
from insulin sensitive or insensitive organs. The exploration of mechanisms concealed behind 
this discrepancy would disclose a potential strategy for cancer treatment through annulment 
of cancer specific effects of insulin. 
The role of mRNA translation during treatments with experimental anti-cancer drugs or those 
used in the clinic is largely unknown. We examined the effect on translation of one such 
experimental drug called “Reactivation of p53 and induction of tumor cell apoptosis” 
(RITA). The α subunit of eukaryotic initiation factor 2 (eIF2α) is a key regulator of 
translation initiation. We found eIF2α to be phosphorylated during RITA treatment and to be 
involved in RITA induced apoptosis and repression of mRNA translation. This activity of 
RITA is independent of TP53 and mTOR pathway. The inhibition of eIF2α phosphorylation 
counteracts the impact of RITA on apoptosis and clonogenicity.  
Another aspect of this thesis explored regulation of translation in immune cells. Short post-
infusion persistence restricts treatment of hematological malignancies via adoptive infusion 
of stimulated natural killer (NK) cells. Interleukin-15 (IL-15) was demonstrated to hold 
stronger ability than IL-2 to maintain antitumor functions of NK cells after cytokine 
deprivation. To explore the mechanism underlying these differences, a transcriptome wide 
study through polysome-profiling technique was applied. Further, the role of mTOR pathway 
in this superiority of IL-15 was also investigated. Coupled with clinical outcome of patients 
with B-cell lymphoma, IL-15 but not IL-2 is argued to be implemented in adoptive NK cell 
cancer therapy. 
In conclusion, in order to facilitate studies of the translatome for samples with low amount of 
RNA and small bio-banked tissues, the optimized non-linear gradient was designed. Its 
performance in aforementioned samples for large experiment set and general applicability 
was verified to be satisfying. The study on cancer specific effects of insulin unraveled the 
prospect to selectively target insulin/IGF1 dependent effects on metabolomes and/or 
translatomes for cancer therapy. As two important pathways regulating translation initiation, 
the effect of mTOR in immune cell functions and eIF2α in RITA induced apoptosis were 
unveiled and explored.  
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1 INTRODUCTION 
1.1 REGULATION OF mRNA TRANSLATION 
1.1.1 Regulation of gene expression  
Mammalian gene expression is commonly divided into multiple regulatory steps including 
transcription (1), RNA modification (2), splicing (3), mRNA transport (4), mRNA 
degradation, mRNA translation (4) and protein degradation (5,6). Following transcription, the 
pre-mRNA is modified by e.g., 5' capping, 3' polyadenylation and RNA splicing to produce a 
mature mRNA. This is followed by export of the mRNA to the cytosol where it can be 
translated into proteins, stored or degraded. Each of these steps is elaborately regulated via 
different mechanisms to assure that the desired proteins are produced in proper amounts in 
response to extracellular signals (7), as is shown in Figure1. Moreover, correct regulation of 
gene expression is vital to maintain cell characteristics including differentiation state. As a 
key step in gene expression, regulation of mRNA translation represents a crucial line to yield 
biological functional macromolecules – proteins responding to cells’ demand. Compared with 
regulation of transcription, regulation of translation can more rapidly affect protein levels as it 
does not require de novo synthesis (or degradation) of mRNA molecules to affect protein 
synthesis. Regulation of translation is involved in a wide range of biological processes such 
as cell growth, development (8), learning and memory (9,10) as well as cellular apoptosis 
(11). Its dysregulation has been observed in a variety of diseases, such as metabolic disorders 
and cancer, etc. (12). Benefitting from fast developing high throughput techniques and 
advances in data processing and analysis, the prominent discrepancy between transcriptome 
and translatome has been revealed, which indicates a complex regulatory mechanisms during 
mRNA translation. Therefore, the exploration of mechanisms underlying regulation of 
translation is necessary and significant to understand how it is controlled and holds a great 
therapeutic potential to treat the diseases with faulty translation. 
 
Figure 1. Levels of regulation of gene expression  
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1.1.2 An overview of regulation of translation 
Protein synthesis consumes the majority of cells’ energy (13). This requires tight and 
dynamic regulation of mRNA translation to ensure that energy demand is matched with 
energy production. Regulation of translation is defined as the modulation of translation 
efficiency (14). This can be exerted at multiple levels, including translation initiation, 
elongation and termination. Initiation of translation is acknowledged as a rate-limiting step in 
translation (15). This is consistent with the common sense that controlling the onset of one 
event is more energy efficient than modulating the speed. According to the scope of regulated 
transcripts, regulation of translation exhibits two regulatory modes – global control and 
selective control.  “Global control” is defined as when translation of almost all mRNAs are 
switched on or off. This is in contrast to selective control, which only influences a subset of 
mRNAs. As mentioned above, sequence and structural features of mRNA, the state of the 
translational apparatus, and the availability and activity of trans-acting proteins affect 
translational efficiency (14). From a general perspective, the elaborate regulation of 
translation is realized through two main principles: one is modification of translation 
initiation factors depending on signaling networks involved in translation; the other is trans-
acting factors that bind to RNA, such as RNA binding proteins and many micro RNAs (16). 
Below, these two principles will be introduced followed by two translation regulation modes 
of global control and selective control.  
1.1.3 Translation initiation factors 
Eukaryotic translation initiation is the process leading to assembly of an 80S ribosome on an 
mRNA (14). This process requires the small 40S and large 60S ribosomal subunits, most 
commonly a minimum of 12 eukaryotic initiation factors and ATP/GTP hydrolysis (14). 
eIF1, eIF1A and eIF3 facilitate the interaction of the ternary complex (TC) with a 40S 
subunit to form a 43S pre-initiation complex (PIC). Association of the 43S complex to the 5’ 
end of mRNA requires the cooperation of eIF4F, eIF4B and polyA-binding protein (PABP) 
(17). eIF4F is a heterotrimer complex that contains eIF4A (an ATPase/RNA helicase of the 
DEAD-box family), eIF4G (a large modular protein as a scaffold which also binds with both 
eIF3 and PABP) and eIF4E which is a cap binding protein (18). eIF4E’s binding to the m7G-
cap is widely acknowledged as the rate-limiting step of cap-dependent initiation (18,19). As a 
key constitutive part of the eIF4F complex which is required in translation initiation, eIF4E is 
involved in leading ribosomes to the cap structure of mRNAs (20). The binding of eIF4E to 
eIF4G acts in an ATP independent manner, while the activities of eIF4A and eIF4B requires 
ATP (21). eIF4F formation can be regulated by 4E-BPs, a family of translation repressors 
(22). The 4E-BPs compete with eIF4G to bind to eIF4E on an overlapping site. Thus, the 4E-
BP binding to eIF4E causes dissociation of the eIF4F complex and thereby inhibits cap-
dependent translation (23). After exposure to a series of extracellular stimuli, such as 
nutrients and mitogens, the 4E-BPs get hyper-phosphorylated on multiple sites such as 
threonines 37 and 46, the phosphorylation of Thr-37 and Thr-46 by mTOR primes the 
following phosphorylation of other Ser/Thr sites with the sensitivity to serum at the carboxy-
terminal sites (24). Mothe-Satney et al. have demonstrated that the phosphorylation of Ser65 
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is subsequently relied on preceding phosphorylation of Thr 37, Thr46 and Thr70 (25,26). 
Another study revealed the order of 4E-BP1 phosphorylation in vivo: Thr37 and Thr46 are 
phosphorylated first, then Thr70, the last is Ser65 (27). Once phosphorylated, 4E-BP 
decreases its affinity to eIF4E, leading to the release of eIF4E and formation of the eIF4F 
complex. PABP interacts with eIF4F complex via eIF4G and binds the poly-A tail of 
eukaryotic mRNA and is thereby thought to promote circularization of the mRNA (28). The 
binding of PABP facilitates PIC attachment to mRNA. The PIC then scans towards the 3’ end 
until it reaches the start codon (AUG) where translation is initiated (29). The process is 
shown in Figure 2. 
 
Figure 2. Sketch of eukaryotic translation initiation process 
1.1.4 mTOR pathway 
1.1.4.1 mTOR complex 
mTOR is a serine/threonine protein kinase which belongs to phosphatidylinositol 3-kinase-
related kinase protein family (30,31). A widely acknowledged function of mTOR pathway is 
to modulate the activity of cap-dependent translation initiation in eukaryotes. Activation of 
mTOR leads to phosphorylation of 4E-BP. This process is involved in many biological 
process such as cell growth, proliferation and survival, protein synthesis, autophagy, 
transcription, etc. (32). mTOR can bind to alternative multi-proteins leading to the formation 
of two distinct complexes: mTORC1 and mTORC2 which demonstrate different signaling 
activities (33), as shown in Figure 3. MTOR-GβL-Raptor (mTORC1) is composed of mTOR, 
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regulatory-associated protein of mTOR (Raptor) and mammalian ortholog of the yeast LST8 
protein 8 (MLST8, also termed as GβL) (34). Rapamycin inhibits mTORC1 function by 
associating with the immunophilin FKBP12. The FKBP12-rapamycin complex blocks 
mTOR activity by binding directly to the FKBP12-rapamycin binding (FRB) domain of 
mTOR (35). mTORC1 can directly phosphorylate its downstream substrates which include 
eukaryotic initiation factor 4E-BP1 (36,37) and ribosomal protein S6 kinase1 (S6K1) (38,39) 
on distinct recognition motifs. For example, the TOR-signaling (TOS) motif at the C-terminal 
end of 4E-BP1 (40) binds to raptor, so also to mTOR. This motif on 4E-BP1 is responsible 
for phosphorylating the sites of Ser64/65 and Thr69/70 (Ser65 and Thr70 are on human 4E-
BP1; Ser64 and Thr70 are in rodent 4E-BP1) in vivo (41). There has been a study showing 
that the RAIP motif (from the single letter code for its amino acid sequence) (42) plays a role 
in amino acids stimulated phosphorylation at the N-terminal sites of 4E-BP1 in a rapamycin-
insensitive manner (41). Besides that, for all discovered S6 kinases, the TOS motif at their N 
terminus is proven to be vital for the phosphorylation and regulation of S6K1 activities (40). 
The TOS motif is of importance both for S6 kinases and 4E-BP1 to be regulated in the 
mTOR pathway since it functions as a site where mTOR and other upstream activators of 
S6K1 and 4E-BP1 can dock (40). 
Instead of binding to Raptor, mTORC2 includes mTOR- GβL-Rictor (orthologous to yeast 
Avo3) which is insensitive to rapamycin (43,44). mTORC2 phosphorylates Ser-473 on the 
serine/threonine kinase Akt to influence metabolism and survival (45), PDK1 can 
phosphorylate a threonine T308 residue on Akt and this leads to full activation of Akt 
(46,47). By stimulating a series of factors such as protein kinase C α (PKCα), paxillin, 
Cdc42, F-actin stress fibers, Rac1 and RhoA, mTORC2 is reported to be a key regulator of 
the actin cytoskeleton (44).  
Dysregulation of mTOR has been found in many diseases, including diabetes, obesity, 
Alzheimer's disease, Parkinson's disease and many cancers like breast cancer and ovarian 
cancer (48,49). As a key signal pathway affecting translation, the role of mTOR in diseases 
such as metabolic disorders, cancer and in immunology will be discussed next. 
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Figure 3. Overview of the PI3K/AKT/mTOR pathway 
1.1.4.2 Insulin induction of mTOR signaling  
Insulin is a hormone which maintains glucose homeostasis via modulating the utilization of 
glucose in peripheral tissues (50,51), where it stimulates anabolic process such as protein 
synthesis and ribosome biogenesis, which mostly relies on nutritional availability (32). 
Several studies have demonstrated that insulin’s role in the anabolic process, most notably in 
ribosome biogenesis and protein synthesis that is mediated by the activation of mTOR/S6K1 
signaling (52-54). The binding of growth factors such as insulin to its receptor makes specific 
tyrosine residues at the intermolecular receptor act as docking sites. One of these sites recruits 
PI3K (55) which facilitates the production of phosphatidylinositide-3,4,5-P3 (PIP3). Enhanced 
number of PIP3 recruits PKB (Also known as Akt) to the membrane where PKB becomes 
phosphorylated at Thr308 and Ser473 through the binding of its pleckstrin homology (PH) 
domain to PIP3 (56-58) (Also see in session 1.2.4.2). After activation, PKB phosphorylates 
tuberous sclerosis complex (TSC) protein 2, the phosphorylation of TSC2 inhibits its 
association with TSC1 (59) which interacts with TSC2, functioning as a tumor suppressor 
complex (60) (Figure 3). In mammals, the suppressive function of TSC1/TSC2 is due to the 
GTPase-stimulating activity of TSC2, which inactivates Ras homolog enriched in brain 
(Rheb) (61) into its GDP state. S6K1 activation induced by insulin was demonstrated to be 
inhibited by TSC1/TSC2 overexpression (62). Consistently, insulin has been proved to 
enhance the level of Rheb1-GTP (63) and elevates mTORC1’s activity to signal to 
downstream factors like 4E-BP1 and S6K1 (64,65). 
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1.1.4.3 mTOR signaling in metabolism 
mTOR activity is highly dependent on nutrients and mitogens such as insulin (66), which is 
consistent with that mTOR plays important roles in mammalian metabolism and physiology, 
especially in tissues such as brain, muscle, liver and white and brown adipose tissues. Studies 
have shown that insulin receptor substrate 1 (IRS-1) deficiency can cause insulin resistance in 
brown adipocytes by affecting insulin oriented lipid synthesis. Moreover, IRS-2 deficient 
hepatocytes fail to respond to insulin due to being incapable to activate PI3K-Akt-mTOR 
pathway (67). The insulin receptor is indispensable for regulation of the mitogenesis of foetal 
pancreatic β-cell mediated by complete activation of mTOR/p70S6K through PI3 kinase and 
MEK-1 pathway. However, glucose induced β-cell mitogenesis, independent of PI3 kinase, is 
induced by MEK-1, which converges on mTOR/p70S6K pathway to regulate foetal β-cell 
proliferation (67).  
As a key mediator of most metabolic processes, mTORC1 is involved in enhancing 
glycolytic flux by stimulating the expression of hypoxia inducible factor 1α (HIF1α) which is 
an enhancer of many glycolytic genes (68-71); by facilitating the association of transcription 
factor Ying-Yang 1 (YY1) and peroxisome proliferator-activated receptor-γ (PPARγ) 
coactivator 1α (PGC1α). mTORC1 has also been reported to enrich mitochondrial DNA 
content and participate in oxidative metabolism by stimulating the expression of 
corresponding genes (72). Further, lipid biosynthesis is mediated by mTORC1 through its 
effects on transcription factors of sterol regulatory element-binding protein 1/2 (SREBP1/2), 
which regulates the translation of a lot of genes e.g., ACC, FASN and SCD1, participating in 
the synthesis of fatty acid and cholesterol (73). Several studies have revealed that for certain 
cell types, mTORC1 control SREBP function through S6K1 (69,74,75). Glycolysis and 
mitochondrial respiration is also mediated by mTORC1 through 4E-BP-dependent 
translational regulation to supply the cellular energy (76). There has been a study 
demonstrating that mTORC1 modulates the activity and biogenesis of mitochondria by 
prioritizing selective translation of nucleus-encoded mitochondria-related mRNAs by 
suppressing 4E-BPs. This selective translation of nucleus-encoded mitochondria-related 
mRNA provides an eligible capacity for ATP production, as an energy source for 
mitochondrial activities (77). Similarly, mTORC2 stimulates AKT to increase glycolytic 
metabolism, and dephosphorylates class IIa histone deacetylases (78,79), which causes 
inactivation of the forkhead box protein O1 (FOXO1) and FOXO3 by acetylation, this further 
activates MYC transcription (76).  
1.1.4.4 mTOR pathway in immunology 
The intercellular homeostasis is central for cell development and proliferation, the innate 
immune system functions as a guardian in response to different kinds of perturbations, thus to 
maintain the cells’ homeostasis (80). There have been several studies demonstrating that 
mTOR is implicated in mediating the functions of innate immune cells by participating in a 
wide network of cellular and metabolic activities affecting immune effector responses.  
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When innate immune cells become activated, they require a reprogramming to remodel their 
metabolism and energy consumption to undergo a series of activities such as changing their 
morphology, migration and secreting cytokines, chemokines and lipid mediators (76). Most 
of these functions act via the activation of the mTOR pathway. mTOR in activated innate 
immune cells is stimulated by growth factors, cytokines and Toll-like receptor (TLR) ligands. 
There have been several studies showing that in dendritic cells (DC) and neutrophils, 
mTORC1 is activated by FMS-related tyrosine kinase 3 ligand (FLT3L) and the growth 
factors granulocyte–macrophage colony-stimulating factor (GM-CSF) (81-83); both 
mTORC1 and mTORC2 are stimulated by TLR ligands in human and mouse macrophages, 
monocytes and DCs (81,84-90); mTORC1 and mTORC2 are activated by IL-4 in mouse 
macrophages (91,92), and IL-15 can induce mTOR activity in both human and mouse natural 
killer (NK) cells (93). As already discussed, mTORC1 signaling is central in regulating 
translation and protein synthesis by modulating the activities of its downstream effectors 
eIF4E and S6K. Therefore, mTOR is of importance in induction of protein synthesis in 
activated innate immune cells. 
In addition, many studies have illustrated that mTORC1 is involved in myeloid cell 
development (94). TLR-stimulated primary myeloid immune cells exhibit an immuno-
stimulatory effect by suppressing mTORC1 or mTORC2. 
NK cells are a type of innate immune cells with cytotoxic lymphocyte capability, they play an 
important role in immune surveillance of cancer and infections (95). In mouse models, the 
proliferation and cytotoxicity of NK cell mediated by IFNγ and granzyme B requires the 
participation of mTORC1 (93,96,97). In NK cells under the inhibition of mTOR by 
rapamycin, the cells stop expressing IFNγ and granzyme B and halt their proliferation (93,97). 
This suppressive influence of mTOR knock down on NK cells’ proliferation and cytotoxicity 
has also been observed in rapamycin-treated transplant human recipients (98). Once mTOR is 
reactivated in NK cells, the cells carry out a multistep of mTOR dependent metabolic 
reprogramming, which leads to increased glucose uptake and more aerobic glycolysis (99). 
The NK cells’ cytotoxicity relies directly on the rate of glycolysis (99). Therefore, NK cells’ 
growth and functionality relies heavily on glucose availability and utilization regulated by 
mTORC1 (76).  
1.1.4.5 mTOR in cancer 
As mentioned above, the disorder and malfunction of mTOR pathway has been observed in 
carcinogenesis of many tumors (100). As a well-known tumor suppressor, TP53 deficiency 
has been found to stimulate mTORC1 activation, while activated TP53 suppresses mTOR 
activity and controls its downstream effects, such as autophagy induced tumor suppression. 
TP53 performs its influence on mTOR by requiring AMP kinase activation and TSC1/TSC2 
complex participation, which both act in energy-deprived cells (101). Furthermore, a growing 
number of studies have exhibited that majority of factors upstream of mTOR signaling are 
mutated in a series of cancers, such as Akt (101,102), TSC1/2 (103), neurofibromatosis type 
1 (Nf1) (104), serine threonine kinase 11 (Lkb1) (105) and Pten (106). The dysregulation of 
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translation initiation downstream of mTORC1, more specifically, 4E-BP1 and eIF4E disorder 
has been considered as a key in cancer formation. These two factors have been demonstrated 
to participate in transmitting the oncogenic effects of Akt on mTOR pathway in protein 
synthesis and tumor development (107). Cells lacking 4E-BPs and thus with overwhelmed 
cap-dependent translation lose their control over cell proliferation, which is originally 
realized by selectively suppressing the translation of mRNAs that encode for proteins with 
stimulatory functions in proliferation and cell cycle progression (108). S6K1 as another 
important target downstream of mTORC1 appears to contribute the maintaining of fast cell 
growth of cancer by being involved in ribosome synthesis, thus it offers a sufficient supply of 
translation machinery (109). As mentioned above, mTORC1 is also involved in lipid 
biosynthesis through transferring growth factor signaling to SREBP1/2 (69,73), the lipid 
biogenesis is highly required in cancer cell proliferation since fatty acids must be created to 
reach the rapid membrane synthesis requirement (110). Even though mTORC2 is not as 
widely studied as mTORC1, several studies have illustrated that mTORC2 is highly involved 
in cancer development. Rictor as a component of mTORC2, has been found to be 
overexpressed in glioma and to endow cells with proliferative and invasive capability 
(111,112). Hence, the activation of oncogenes conveys a series of signaling to mTOR 
complexes which increases a variety of activities in protein synthesis, cell proliferation, 
survival, anti-apoptosis required for cancer initiation and development. 
1.1.5 eIF2α pathway  
The eIF2α pathway, as another important signal pathway in addition to mTOR, also 
participates in eukaryotic cap-dependent initiation. eIF2 is a G-protein switch which delivers 
the initiator methionyl-tRNA (Met-tRNAi) to ribosome. The process starts with the binding 
of the TC which involves the met-tRNAi and GTP bound eIF2 to the small (40S) ribosomal 
subunit, this forms the 43S PIC (113). Comparing to eIF2-GDP, eIF2-GTP has stronger 
affinity to Met-tRNAi (114). There has been a study showing that eIF2𝛾 can bind directly to 
GTP and Met-tRNAi, eIF2α and eIF2𝛽 subunits are involved in increasing this affinity to 
Met-tRNAi almost one hundred times. However, the exact mechanism behind this is still 
largely unknown (115,116). Under the help of a series of aforementioned initiation factors 
such as PABP, eIFs, 4B, 4H and 4F, 43S PIC binds to the mRNA at the location of the 5’-7-
methylguanosine cap and then scan the five prime untranslated region (5'-UTR) until it 
reaches the start codon AUG. Base-pairing between the start codon AUG and anticodon of 
Met-tRNAi is considered as the beginning of start codon recognition (117-119). Then eIF2 
will release phosphate which turns itself from eIF2-GTP to eIF2-GDP, following this process 
with presence of other initiation factors, the large 60S subunit binds to the complex to form 
the 80S, which represents the end of translation initiation and a start of elongation (120). 
1.1.6 Trans-acting factors — RBPs in regulation of translation 
Regulation of translation is under elaborate control by a complex of molecular mechanisms.  
Among which, RNA-binding proteins (RBPs), trans-acting factors and small RNAs revamp 
mRNA translatability by binding to certain regions of the mRNA (121). Cis-regulatory 
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elements (CREs) are one of these regions of non-coding sequence that RBPs bind to. These 
regions are tightly involved in regulation of translation and more often found in 5'-UTR 
and/or three prime untranslated regions (3'-UTR) (16). The 3'-UTR contains binding sites for 
RBPs and miRNAs which usually have inhibitory effects on translation or cause degradation 
of the transcripts (121,122). At the step of translation initiation, eIF4G, as a scaffold protein, 
binds with initiation factors and PABP which binds to polyA tail of 3’-UTR to form a closed 
loop. The formation of this loop is often affected by RBPs. A study in drosophila, for 
example, has demonstrated that bicoid binds to the 3’-UTR of mRNA, this leads to the 
recruitment of 4E homologous protein (4EHP, in mammals known as eIF4E2) to the 5’ cap, 
which decreases the translation due to 4EHP’s low affinity with eIF4G (121). Moreover, 
there have been studies showing that RBPs also cooperate with  other factors to regulate 
translation, such as miRNAs (121). For example, the regional secondary structure of the 3’-
UTR of p27 mRNA is altered by binding of pumilio-1 (PUM1), which facilitates miR-221 
and miR-222 to target the sites to perform their inhibitory functions (123). In contrast, the 
protein Dead end 1 (Dnd1) competitively binds to the overlapping sites to inhibit miRNA-
mediated silencing (124).  
One example of an RBP is upstream of N-ras (UNR), as a conserved RBP in drosophila, 
executes its functions of controlling mRNA translation and maintaining stability through the 
similar mechanism like other RBPs via binding to specific sequences in UTRs. Along with 
the non-coding RNA roX, male-specific lethal2 (msl2) mRNA bound by UNR is 
acknowledged to be involved in regulating drosophila dosage compensation which is a 
process whereby genes on the male X chromosome is hyper-transcribed to compensate and 
equalize the expression level of genes on X chromosome between female (XX) and male 
(XY) (125). The suppressed expression of msl2 is indicated to repress dosage compensation 
in females. This suppression of msl2 is mediated by another RBP — sex-lethal (SXL), which 
in the nucleus, inhibits mRNA splicing by binding to oligo uridine segments of the 5’UTR of 
msl2, while in cytoplasm, SXL exerts its inhibitory function via adhering to 3’UTR (126). 
Several studies have revealed that UNR engages itself in different mechanisms by combining 
distinct regulatory sequence to control mRNA translation in a gender specific style (127,128). 
A study has illustrated that UNR inhibits MSL2 mRNA translation via disrupting the 
packaging of MSL dosage compensation complex (MSL–DCC) in females (129). However 
for males, UNR stimulates and facilitates the MSL–DCC to target the X-chromosome in an 
MSL independent manner (128,130). Moreover, UNR is acknowledged of its function in 
facilitating the translation mediated by internal ribosome entry sites (IRES) and retaining the 
stability of mRNA in mammals (131,132). Wurth, et al. have indicated that the expression of 
UNR is increased in melanoma tumors which stimulates tumor’s invasion and metastasis 
(133). Besides, UNR coordinately regulates novel pro-metastatic RNA regulons. As a RBP, 
UNR not only plays a role in maintaining RNA steady-state levels, but also participates in 
regulating some of its targets such as VIM (Vimentin) and RAC1 (Ras-related C3 botulinum 
toxin substrate 1) mRNAs on the translation elongation level (133). There has also been a 
study demonstrating that the low expression of UNR by immunohistochemistry using a tissue 
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microarray was significantly associated with poor prognosis after surgery in patient with 
pancreatic ductal adenocarcinoma (PDAC) (P = 0.010) (134). 
As another important RBP, HuR selectively binds to and stabilizes mRNAs containing 
adenylate-uridylate-rich elements (ARE). This stabilizing capability is realized by binding to 
AREs and preventing their degradation. It transports mRNAs containing ARE in the 3’UTR 
from the nucleus to the cytosol. There has also been a study showing that HuR antagonizes 
miRNA function by self-oligomerization along the 3’-UTR and cause the detachment of 
miRNA (135). HuR plays a vital role in stabilizing the mRNA of central molecules or 
cytokines involved in carcinogenesis (136) and subsequent progression such as cell 
proliferation, angiogenesis, invasion, metastasis and immune evasion (137). Due to HuR’s 
preventive effect on mRNAs from degradation, it indirectly enhances protein production and 
is involved in the control of differentiation process. HuR was found to enhance the expression 
of many growth-promoting, proliferative and proto-oncogenic factors like epithelial growth 
factor (EGF), c-myc and c-fos, GM-CSF, cyclin A, B1 and D1, pro-angiogenic factors such 
as HIF-1a and VEGF, and anti-angiogenic factors like thrombospondin 1 (TSP1). Thus, as an 
RBP, HuR is involved in regulation of translation and influences the expression of numerous 
traits vital to the development and progression of cancer.  
1.1.7 Regulation of global translation  
Fertilized invertebrate eggs and mammalian iron-starved reticulocytes were the cases studied  
earliest on global translational regulation in which all mRNAs are regulated in unison (14). 
This united regulatory pattern of protein synthesis that turning on in fertilized eggs and 
turning off in iron-starved reticulocytes happens in absence of transcription (120). The global 
translation is usually realized via changes of protein synthesis machinery components (14). 
For example, a wide variety of stresses conveying the signals to phosphorylate eIF2α through 
activating nuclear factor κB (NF-κB) which regulates gene transcription (138,139). Such 
stress conditions include pro-inflammatory cytokines exposure, UV irradiation, 
microorganism infection, and damaged protein folding in the endoplasmic reticulum (ER) 
(138). As a key to regulate protein synthesis, guanine nucleotide exchange factor (GEF) 
eIF2B changes eIF2-GDP to its transnationally active eIF2-GTP form (140,141). Once eIF2α 
is phosphorylated at serine 51, as a constitutional functional group in the regulatory 
subcomplex of eIF2B, this complex converts eIF2 to a competitive inhibitor of GEF (142). 
As a result, eIF2-GTP levels are reduced and translation initiation is globally suppressed to 
reserve energy, and cells adapt themselves to a new gene expression program to avoid cell 
damage caused by aforementioned stresses (143). The other signaling pathway controlling 
global translation is mTOR pathway. It is mTORC1 that regulates global protein synthesis via 
phosphorylating specific effector proteins 4E-BP1, this results in eIF4E released from 4E-
BP1 and then facilitates translation initiation by forming eIF4F complex. These consecutive 
events are generally considered as the dominating mechanism by which mTOR mediates 
global translation (18). It is worth mentioning that mTOR also regulates selective translation 
by preferentially accelerating the translation of some selected groups of mRNAs, among 
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them, one subset with relatively long and structured 5’ UTRs are termed as “eIF4E sensitive” 
mRNAs (144), which will be discussed in the next section. 
1.1.8 Regulation of selective translation 
In contrast to global control, selective control regulates the translation of a subset of mRNAs 
in a cell, or even merely a single mRNA species under extreme condition. Such regulation 
can occur in tune with factors specific to individual mRNAs or classes of mRNAs (such as 
RBPs discussed above), or via modulating the activity of certain translation machinery 
components, such as eIF4E (14). The mRNA subsets translated preferentially via modulation 
of eIF4E activity are termed as “eIF4E-sensitive” mRNAs which commonly have long and 
structured 5’UTRs (144-146). This feature makes eIF4E sensitive mRNAs rely more on the 
unwinding activity of eIF4A (A DEAD (Asp-Glu-Ala-Asp)-box RNA helicase) in eIF4F 
complex (147). The mRNAs in this subset encode proteins such as vascular endothelial 
growth factor (VEGF) (148), cyclins (149), c-Myc (150) and ornithine decarboxylase (151), 
which participate in cell survival and proliferation (108). A recent study identified a new 
subset of mRNAs produced from nuclear encoding proteins involved in mitochondrial 
functions (such as ATP5O, ATP5G1) as being sensitive to eIF4E, but this new subset of 
mRNAs lack a long 5’UTR (152). These short 5’UTR mRNAs have plenty of translation 
initiator of short 5’UTR (TISU) elements (153). Another example of selective regulation of 
translation is integrated stress response (ISR) dependent eIF2α phosphorylation, which also 
induces the translation of select transcripts. For example, activating transcription factor 4 
(ATF4), whose activation stimulates the transcription of genes subject to ISR (143). For more 
advanced eukaryotes, such as mammalian cells, mitogen-activated protein kinase (MAPK)-
interacting kinases (MNK) 1 and 2 bind to the C-terminal region of eIF4G, and phosphorylate 
eIF4E under stress and mitogen stimulation condition (154-156). eIF4E phosphorylation 
selectively stimulates the translation of mRNAs involved in survival (157) and tumor 
invasion (158). There has been a study showing that mTORC1 tends to initiate translation 
of mRNAs with a 5′ terminal oligopyrimidine tract (5′ TOP) or with a pyrimidine-rich 
translational element (PRTE, whose position is recently reported to be not strictly within 
the 5' UTRs) (159). These structures are manifested to encode the components of 
translational apparatus (160,161) and proteins involved in translation and metabolism 
(162,163). Another study shows that in oxygen deprived cells, TOP mRNAs show a TSC-
Rheb-mTOR dependent manner, but independent of 4E-BPs (164). This was proven by 
experiment setup in 4E-BP loss- and gain-of-function studies that the phosphorylation status 
of 4E-BP did not contribute to a cause for the translation inhibition of TOP mRNAs under 
growth factor deficiency or hypoxia conditions (164).  
1.1.9 Regulation of translation in cancer 
The dysregulation of translation can lead to a variety of abnormalities, such as imbalance in 
proliferation, aberrant angiogenesis, prolonged survival, disorder in immune response and 
cancer energetics. The dysregulation of translation has been found in many types of cancers 
(165-168). Cancer is frequently found with a series of amplified and/or dysregulated 
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translation initiation factors (146). For example, eIF4E overexpression causes poor prognosis 
in breast (169), head and neck (170), stomach (171), bladder (171), liver (172) and prostate 
cancers (172); overexpression of 4E-BP1 is oppositely correlated with tumor grade (173); 
eIF4G overexpression correlates with lung (174), breast (175) and cervical cancers (176); 
increased expression of eIF4A can be found in lung (174) and cervical cancers (176); loss of 
PDCD4 is associated with poor outcome in breast (174), lung (177), colon (178) and ovarian 
cancers (179). Moreover, enhanced expression of eIF2α is associated with aggressive 
lymphoma subtypes (179); overexpression of eIF3a is associated with breast, esophageal, 
stomach, lung and cervical cancers (179). All these dysregulated translation initiation factors 
in cancers are listed in Table 1. Breast cancer shows elevated eIF4E phosphorylation (180), 
4E-BP1 phosphorylation (173,181), overexpression of eIF4G (175), decreased level of 
PDCD4 (182), increased level of eIF3a (183), b (184), h (185), i (186) subunits, decreased 
expression of eIF3e (187) and f subunits (188). Moreover, some of the most common cancer-
related mutations, such as mutations of MYC, RAS and PIK3CA have been found to affect 
the translation machinery (146). Indeed, many oncogenic signals affect translation machinery 
components, and most cancer cells show an increased activity of the translation machinery. 
Thus, this suggests that tumors are addicted to selective changes in protein synthesis (146). 
Therefore, the treatment targeting these translational programs may be a promising strategy to 
treat cancer (189). 
Table 1. Dysregulation of translation initiation factors in cancers 
Factors Dysregulation Consequences in cancers 
eIF4E  Overexpression Poor prognosis in breast, head and neck, liver, prostate, 
bladder and stomach cancers 
4E-BP1 Overexpression  Oppositely correlated with tumor grade 
eIF4G  Overexpression Correlates with lung, breast and cervical cancers 
eIF4A  Up-expression Overexpressed in lung and cervical cancers 
PDCD4 Loss Associated with poor outcome in breast, lung, colon, 
and ovarian cancers 
eIF2α Enhanced expression Associated with aggressive lymphoma subtypes 
eIF3a Overexpression Associated with breast, cervical, esophageal, lung and 
stomach cancers 
 References are listed in the paragraph of section 1.1.9. 
The dysregulation of translation has been proven to be involved in many human disorders and 
diseases. Cancer, as a spectrum of severe and sharply increasing syndrome in recent decades, 
will be further discussed in this thesis from here on. 
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1.2 CANCER 
1.2.1 Cancer hallmarks and therapeutic challenge 
Cancer is a large variety of diseases arising from uncontrolled cell growth with the 
characteristic to invade and/or metastasize to adjacent and distance sites from the original 
lesion. Cancerization as the replacement of the normal cell population by a cancer-primed 
cell population (190), commonly starts as a long period ahead of a clinically detectable mass 
and certain obvious symptoms. Cancerization is a complex and multistep process including 
genetic mutations and epigenetic alterations. These genetic and molecular changes 
differentiate cancer from normal tissues by rendering them a series of distinctive and 
complementary capabilities to fuel the growth and metastatic dissemination of a tumor. Those 
capabilities, in other words, hallmarks can be categorized and summarized as below: 
imbalance between proliferative and inhibitory signaling, avoidance of apoptosis, 
immortalized replication, sustained angiogenesis, tissue invasion and metastasis, escaping 
from immune surveillance, tumor-oriented inflammation, energy metabolism reprogramming, 
genome instability and mutation (191), and replication stress (Figure 4) (192).  
 
Figure 4. Hallmarks of cancer.  
Adapted from Hallmarks of Cancer: The Next Generation. Hanahan, D. and Weinberg, R.A. (191) 
The therapeutic strategy targeting the mechanism behind each hallmark has naturally been 
introduced and studied widely for ages. For example, VEGF signaling inhibitors can be used 
to offset the induction of angiogenesis; replicative immortality can be suppressed by 
telomerase inhibitors; selective anti-inflammatory drugs can extinguish tumor induced 
 14 
inflammation, etc. It is worth mentioning that most of the hallmark-targeting drugs were 
designed to act specifically against one particular cancer capability, in order to reduce off-
target effects and to avoid nonspecific toxicity. However, this presumed virtue has failed to 
produce a long lasting clinical response, for most cases being followed by an inevitable 
relapse (191).  
According to Hanahan and Weinberg, one explanation for this failure is that many signaling 
pathways converge to contribute to one particular hallmark capability. Therefore, only a 
simplex therapeutic drug targeting one specific pathway is not sufficient to occlude a 
hallmark capability. On the other hand, the cancer cells can adapt themselves to the stress 
imposed by the applied therapeutic agent, adjust and survive to be more relied on the other 
hallmark capabilities to overcome the potencies of the targeting drugs. As a consequence, 
only a combination of therapeutics targeting multiple hallmark capabilities can generate a 
more effective and non-relapsed clinical results (191).  
1.2.2 Genetic and epigenetic alterations in cancer 
A mutation is a stable alteration of the nucleotide sequence in the genome. It can happen by 
chance during DNA replication and be triggered by exposure to various mutagens, like 
carcinogens or radiation. Due to the variety and complex of mutations, there are several ways 
to classify mutation types from different aspects. Based on the scale of nucleotides affected, 
they are categorized as small-scale mutations or large-scale mutations. For small-scale 
mutations, only one gene or a few nucleotides are changed. This includes deletion, insertion 
and substitution of one or several nucleotides in DNA. Depending on which kind of 
erroneous codon being produced, the point mutations which happen in the protein coding 
region can be classified into silent mutations which yield the same or a highly similar amino 
acid, missense mutations that encode for a disparate amino acid, and nonsense mutations 
which result in a stop codon or a shorter protein. The large-scale mutations are the structural 
and/or numerical alterations of chromosomes or chromosome loci. This includes for example 
the deletions of large chromosomal regions, duplications causing double or multiple copies of 
certain region within a chromosome, inversions changing the orientation of a chromosomal 
segment, substitutions as a region from a chromosome becomes a new region in a non-
homologous chromosome, and translocations as interchange of a segment from non-
homologous chromosomes. 
Mutations exist widely in both normal and cancer cells. The biological activity of normal 
cells is under strict control through a series of molecular networks from their birth to death, 
thus the normal cells are able to repair or eliminate the genetic errors. If cells are 
overwhelmed by the errors, they will start programmed cell death which leads to apoptosis. 
However, cancer cells lost this rigorous control, instead of apoptosis, they keep accumulating 
genetic errors and entail them to their progeny. However, not all mutations retain the ability 
to transform normal cells into cancer cells. Normally only 25% of them are the “driver 
mutations” which can lead to a cancer initiation and progression (193). Eventually, the 
accumulation of these genetic disorder leads to an alteration of their genome, they gain the 
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capability to invade and metastasize to distance tissues, and a series of malignant 
characteristics aforementioned. 
Unlike the genetic alteration, epigenetics is defined as a heritable phenotype due to alterations 
in chromosome without changes in the DNA sequence (194). Epigenetic alterations can either 
cause an activation or a silencing of certain gene, which guarantee the cells to express the 
genes that are essential to their utility in a differentiation process. The most common 
epigenetic changes involve DNA methylation, histone modification and micro-RNA gene 
silencing (195). An epigenetic malfunction plays an even more vital role than genetic 
mutations in transforming normal cells to cancer cells (196). Compared to normal cells, the 
hyper-methylation of CpG islands (epigenetic promoter) in cancer, appears over ten times 
more frequent to cause a transcription silencing than by genetic sequence alterations (193). 
Due to the variety of epigenetic disorders and their crucial role in cancer development, 
controlling and correcting epigenetic malfunction discloses a promising therapeutic strategy 
for cancer prevention and treatment. 
1.2.3 Oncogenes and tumor suppressor genes 
In 1941, Theodor Boveri firstly indicated the concept of oncogene in his book “The origin of 
malignant tumors”. He described the oncogene as substances amplified during tumor 
development. Src (proto-oncogene tyrosine-protein kinase Src) was the first discovered 
oncogene in 1970, which was found in a chicken retrovirus (197). An oncogene is derived 
from a proto-oncogene with certain accumulated mutations and an increased level of 
carcinogenesis, which endows normal cells the ability to turn themselves into cancer cells. A 
proto-oncogene, as a normal gene exists in the genome, encodes for proteins largely involved 
in cell proliferation and differentiation. When the proto-oncogenes undergo a series of 
structure modifications, such as mutations within the regulatory region, gene duplication or 
chromosomal translocation, they become oncogenes (198). The most common proto-
oncogenes are for example MYC, RAS, WNT, extracellular signal–regulated kinases (ERK), 
and tropomyosin receptor kinase (TRK) (199). When the normal cells are accumulating 
mutations in proto-oncogenes, with the overcome of apoptosis and restriction of tumor 
suppressor genes, these abnormalities will coordinately turn the normal cells into cancer cells 
(200). The classification of oncogenes has not reached to a united agreement yet, based on 
factors they affect, they are categorized as growth factors (c-Sis), receptor tyrosine kinases 
(EGFR, PDGFR, VEGFR) (201), cytoplasmic tyrosine kinases (Src-family, Syk-ZAP-70 
family), cytoplasmic serine/threonine kinases and their regulatory subunits (Raf kinase), 
regulatory GTPases (Ras protein) (202), transcription factors (myc gene) (203). 
On the contrary, a tumor suppressor gene (TSG), also termed as antioncogene, is a type of 
genes encoding for proteins that are involved in cell cycle and apoptosis, thus can protect 
cells from turning into cancer. Its existence was firstly discovered by Knudson in 1969 (204). 
Carcinogenesis initiates when gain-of-function mutations happen in proto-oncogenes and 
loss-of-function mutations occurs in tumour suppressor genes (205). Most antioncogenes 
follow the principle of “two-hit hypothesis”, which means an effect can only appear when 
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both alleles coding for a specific protein are influenced (204). However, not all the TSGs 
obey the “two-hit hypothesis”, such as TP53, which is the most widely studied antioncogene 
(206). The p53 protein encoded by one mutated allele can counteract the effect of normal 
protein encoded by non-mutated allele, this indicates that the mutation of only a single allele 
of TP53 enhances the possibility to cancer development (207). The inactivation and loss of 
TP53 has been found in a variety of cancers, including leukaemia, lymphomas (208), 
sarcomas (209), brain tumors (210), breast (211), colon (212) and lung carcinomas (213), etc. 
Nevertheless, the first TSG was Rb instead of TP53 which was discovered in retinoblastoma 
(214). With more studies of Rb, it has been found to be involved in a series of cancers, such 
as bladder, breast and lung carcinomas. Other TSGs include for example BRCA1/2 (215), 
NF1/2 (216), PTEN (217), VHL (218) and WT1 (219).  
1.2.3.1 TP53 gene overview 
TP53 gene which resides on the short arm of chromosome 17 (17p13.1) in humans, encodes 
tumor suppressor p53. The most important function of this protein is to prevent normal cells 
from transformation to cancer cells (220). Due to the ability to maintain genome stability, 
TP53 has been honored as “the guardian of the genome” (221). The given name of p53 was 
because it appeared as a 53-kilodalton (kDa) protein on SDS-PAGE when it was first 
discovered. But the real mass of p53 protein is 43.7 kDa. This deviation is because of high 
content of proline in p53 which drags its migration on SDS-PAGE. p53 functions as a central 
pivot in a series of networks. Its inactivation and malfunction has been observed in more than 
50% human tumors, such as prostate, breast, colon and lung cancers, etc. (222,223). 
1.2.3.2 Functions of p53 
p53 shows a variety of antitumor functions, including inducing apoptosis (224), maintaining 
genomic stability (225) and inhibition of angiogenesis (226). These biological functions have 
been widely studied. There have been studies demonstrating that p53 usually associates with 
its negative regulator mdm2 as a complex, this association maintains p53 in an inactive status 
in normal cells (227). Once when cells suffers from a variety of stresses, such as UV 
radiation, ionizing radiation, chemicals, oxidative stress, osmotic shock, and DNA damage, 
p53 will dissociate from mdm2 and become activated (227). The activated p53 on one hand 
acts as a promoter to enhance the activity of DNA repairing proteins to mend the damaged 
DNA, if the damage cannot be repaired, p53 induces initiation of apoptosis (228); on the 
other hand, p53 binds to DNA and activates the expression of genes for instance microRNA 
miR-34a (229), p21 encoded by WAF1/CIP1 and numerous of other genes, among these 
genes, p21 inactivates the G1-S/CDK complex which plays an important role in G1/S 
transition, thus to stop cell proliferation and maintain the cell at the G1/S regulation point 
(228), providing more time for DNA repairing proteins to mend the damaged DNA. 
However, wild type p53 is very unstable with many folded and unstructured regions, 
resulting in a status of continuous synthesis and degradation. Once p53 is mutated, e.g., on 
R175H and R249S (230), it will lose its anti-proliferation ability by decreasing its affinity to 
DNA. As a result, less p21 will be produced to slow down the speed of cell proliferation 
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(231). In addition, p53 is also indispensable in differentiation of human embryonic stem cells 
(hESCs) and the maintenance of stemness in adult stem cell niches (232). There has been a 
study demonstrating that hESCs keep p53 in a low active status (233), the increased activity 
of p53 will cause a fast differentiation of hESCs (234). Knocking out p53 delays the 
differentiation of hESCs, and the rescue of p53 stimulates a spontaneous differentiation of 
hESCs. This explicates that p53 plays an indispensable role in hESCs’ differentiation.  
1.2.3.3  Regulation of p53 
As p53 locates at the key position of several biological networks, its regulation also requires 
the participation of a variety of factors. Upon activation of p53, the N-terminal domain of p53 
will be phosphorylated, this domain has a lot of phosphorylation sites which function as the 
primary targets for protein kinases conveying stress signals (235). There are mainly two 
groups of proteins kinases which interact with the transcriptional activation domain of p53. 
One group is the MAPK family, and the other is ATR, ATM, and CHK1 (236). As previously 
mentioned, mdm2, as a negative regulator of p53, binds to and covers the p53 transactivation 
domain, then prohibits p53 to induce target genes’ transcription (237). Moreover, mdm2 is 
also an E3 ubiquitin ligase which captures p53 and recruits small ubiquitin proteins to the 
p53, leading the poly-ubiquitinated p53 to be degraded by the proteasome system (238). The 
ubiquitin/proteasomes system is a highly regulated machinery which undergoes intracellular 
protein degradation and turnover by proteolysis.  
In addition, p53 also induces the transcription of mdm2. This forms a negative feedback loop 
for these two factors, once mdm2 is produced, it will lead to more p53 degradation (239). The 
excessive mdm2 leads to less functional p53, this could increase the possibility of 
carcinogenesis. There has been a study showing that many tumors are found to be with an 
increased level of mdm2, such as sarcomas (240). On the contrary, an organism without 
mdm2 is not able to survive. Mice without mdm2 during embryonic development has been 
found to end up in death caused by overwhelmed apoptosis. The lethality can be rescued by 
backcrossing to p53 null mice (241,242). Besides mdm2, p53 is also regulated at 
transcriptional and post-translational level; modifications at the post-translational level 
involves for example, phosphorylation, acetylation, ubiquitination and methylation, etc.(243). 
p53 can both function as a transcriptional activator and a transcriptional repressor by directly 
binding to DNA through its DNA binding domain (244). Transcriptional machinery will be 
summoned by p53 to the promoter-enhancer region of its target genes. These activated target 
genes will then be transcribed into corresponding microRNAs and translated to their 
corresponding proteins, thus to transduce and execute p53 functions. By binding to DNA, p53 
can in some situation act as a transcriptional repressor, inhibiting the transcription of certain 
genes, such as bcl-2 gene which is with the function of anti-apoptosis (245).   
1.2.3.4 p53 and diseases 
Considering the important functions of p53, its suppression and deletion has been found in 
many types of diseases. If the mutation of p53 occurs in germ line cells, it can cause a severe 
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hereditary disease named as Li–Fraumeni syndrome (Firstly found by two U.S physicians, 
Frederick Pei Li and Joseph F. Fraumeni, Jr.) (246). As a rare autosomal dominant disorder, it 
causes sarcoma, breast, leukemia and adrenal gland (SBLA) syndrome (246). In addition, p53 
mutation and malfunction has been found in over half of all human tumors. One of the most 
common infectious viruses — human papillomavirus (HPV) suppresses the p53 protein 
function by secreting proteins E6 and E7, E7 also inactivates pRB and CKIs (247), causing 
the escape of cell apoptosis and unrestricted cell proliferation. The infection of the low risk 
HPV subtypes leads to warts, and the high risk HPV subtypes infection, such as types 16 and 
18, causes a cervical dysplasia. The accumulative influence of high risk HPV infection for a 
long time will finally initiate a cervical carcinoma in situ and followed up by a metastatic 
cancer (248).  
1.2.4 Signaling pathways in cancer 
Cancer is a spectrum of diseases involving disorders of many signaling pathways. Such 
pathways include for example regulating cell growth and proliferation responding to cellular 
environment. Ras, PI3K and mTOR signaling plays important roles in this matter; nuclear 
factor-κB transcription factors are involved in tumor development and progression; tumor 
vascularization and metastasis is orchestrated by hypoxia-inducible factor (HIF), functioning 
as a transcriptional factor in nutrient stress signaling. Further, a lot of signaling pathways 
participate in tumors' distant metastasis. However, no thesis of this length can pretend to 
completeness covering all molecular disorders of signaling pathway involved in cancer 
initiation and progression. So, the next two sections will be briefly focused on the Ras-ERK 
and PI3K-Akt signaling pathways that are largely implicated in many steps associated with 
cancer. Also, both of them impinge on mRNA translation and therefore are of interest here, 
1.2.4.1 Ras-ERK pathway 
The activation of Ras-ERK pathway is either through mutations in Ras or Raf gene, which 
leads to activation of these proteins consecutively, or via inactivating GTPase-activating 
proteins (GAPs), such as NF1 (249), DAB21P (250) and RASAL2 (251). These proteins 
promote the hydrolysis of GTP bound to Ras, thus they cause the inactivation of Ras (252). 
As an important transcription factor, Myc which is downstream of Ras-ERK and many other 
pathways, can be phosphorylated by ERK, this phosphorylation prevents Myc from 
degradation caused by ubiquitylation (253). The abnormal expression of Myc has been found 
in many types of cancers, such as Burkitt lymphoma (254), cervical, colon, breast, lung and 
stomach carcinomas. Myc plays a multi-functional role as it is involved in cell cycle 
progression, cellular differentiation and apoptosis (255). The role of Myc in inducing cell 
proliferation is realized by stimulating a variety of genes that function as promoters in cell 
proliferation. These includes G1/S cyclins, CDKs, and the transcription factors in E2F-family 
which drives the cell cycle progression (256). Besides, Myc also stimulates the expression of 
genes functioning in increasing translation and anabolic metabolism, and Myc suppresses the 
genes that induce cell differentiation and blocks the activity of cell cycle inhibitors (252).  
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In addition to Myc, ERK can also phosphorylate a series of kinases, such as mitogen and 
stress activated kinase (MSK), multiple kinases in the ribosomal S6 kinase (RSK), MAPK 
and MNK. Once phosphorylated, these kinases will further enhance the activities of 
transcription factors which participate in cell cycle progression. Under the induction of 
mitotic stimuli, MSKs mediate the phosphorylation of histone H3 at S10 (257). There has 
been a study showing that in mice with the deletion of MNKs phosphorylation site, the cells 
are not able to transform themselves into tumors (258). This revealed the important role of 
MNKs in tumor initiation. It has been demonstrated that by phosphorylation of translation 
initiation factor eIF4E, MNKs are involved in translation initiation (257). Moreover, mTOR 
pathway can also become activated by RSK activation stimulated by ERK. The activated 
RSK can phosphorylate TSC2 that binds with TSC1 as a complex to block the mTOR 
activation. Upon phosphorylation of the complex, the inhibition on mTOR will be relieved. 
Besides, RSK also phosphorylates eIF4B, which further binds with translation initiation 
factor eIF3, thus to increase the translation initiation. An overview of this pathway can be 
seen in Figure 5. 
 
Figure 5. The Ras-ERK and PI3K pathways. 
1.2.4.2 PI3K-Akt signaling pathway 
The PI3K/AKT pathway functions as an indispensable signaling in controlling cell cycle and 
cell proliferation, and its aberrant activation has been largely implicated in many cancers with 
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reduced apoptosis and hyper-proliferation. PI3K signaling is initiated by the growth factor 
and cytokines that bind to the tyrosine kinase receptor, and this leads to the receptor 
dimerization. The factors that have been proven to stimulate this pathway include EGF (259), 
insulin (260), IGF-1 (261) and CaM (262). However, genetic mutations hold the capability to 
activate PI3K-Akt pathway even without growth factors. A lot of mutated genes in cancer 
commonly influence PI3K-Akt pathway by encoding targets or components of this pathway 
(252). A series of proteins involved in this pathway can be affected either through 
amplification or activation of gene mutations, such as PIK3CA which is the type I PI3K 
isoform, adaptor protein PIK3R1 and Akt; or via deletion or inactivating mutations which 
happens in the phosphatases with hydrolyzing function on phosphatidylinositol 3,4,5-
trisphosphate (p1p3) which functions as a PTEN and an INPP4B tumor suppressor (252). 
Once activated, lipid kinase PI3K is recruited to the internal docking site and becomes 
activated. The activated PI3K then stimulates membrane lipids PIP2 to transform into the 
active PIP3 form, this leads to activation of the key signaling kinase AKT. AKT activation 
initiates several downstream processes such as activating CREB (261), inhibiting p27 (260), 
blocking FOXO activity by localizing FOXO in the cytoplasm (260), activating PtdIns-3ps 
(262) and promoting cell growth through protein synthesis by activating mTOR (260), which 
further affect transcription of p70 or 4EBP1(260). On the contrary, there are also a series of 
factors antagonizing this pathway such as PTEN (263), GSK3B (261) and HB9 (259). 
1.2.5 Breast cancer 
1.2.5.1 Breast cancer snapshot 
Breast cancer is a spectrum of diseases with heterogeneous clinical and morphological 
entities, which are distinctive in clinical history and prognosis. The optimized polysome-
profiling mentioned in the first constituent paper aimed at dealing with hundreds of bio-
banked breast cancer tissues, thus to explore the characterization of breast cancer by 
differential translation; the second and the third constituent papers also enrolled breast cancer 
cell line MCF7. Therefore, breast cancer will be introduced next in brief. 
Majority of breast cancer originate from the lining of the lobules and milk ducts, which are 
named as lobular carcinomas and ductal carcinomas, respectively (264). Risk factors for 
breast cancer include family history, benign breast disease, inherited mutations in the BRCA1 
or BRCA2 genes (265), obesity, hormone replacement therapy during menopause, overdose 
of radiation and aging (264,266). Several tests are used to diagnose breast cancer including 
physical exam, mammogram, ultrasound exam, computed tomography (CT) or magnetic 
resonance imaging (MRI) and biopsy. In addition, the level of hormone receptors such as 
estrogen, progesterone and human epidermal growth factor type 2 receptors can also provide 
information regarding aggressiveness, prognosis and therapeutic regimen (264). 
Histologically, based on the degree of tumor cell differentiation, breast cancer is classified 
into well, moderately and poorly differentiated (marked as Grade 1,2,3 correspondingly). 
Staging is based on the extent and distribution of the tumor in the body and therefore affects 
treatment strategies. The most acknowledged staging method is TNM (T: tumor size; N: 
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lymph node involvement; M: tumor metastasis). Stages of breast cancer are classified into 
Stage 0 (Carcinoma in situ) to IV (Metastasis to other part of the body). The standard 
methods to treat breast cancer mainly include surgery, chemo-radiotherapy, hormone therapy 
and targeted therapies (267).  
1.2.5.2 Epidemiology 
Breast cancer is a highly frequent cancer among women in developed countries (268). With 
increased life expectancy, urbanization and adoption of a western life style, the incidence of  
breast cancer is swiftly rising in traditional low-incidence Asian countries such as Japan 
(269), Singapore (270) and China (271). The Surveillance, Epidemiology, and End Results 
Program of the National Cancer Institute (SEER) showed 246,660 estimated new cases in 
2016, which accounted for 14.6% of all new cancer cases. Moreover there were 40,450 
estimated deaths in 2016 which was equivalent to 6.8% of all cancer deaths (272).   
1.2.5.3 Classification 
As mentioned above, the main breast cancer category considers tumor’s histopathology and 
receptor status. Histopathological classification is the category that pathologists use most to 
describe tumors. According to the 2012 World Health Organization (WHO) classification of 
breast tumors (273), breast lesions mainly include invasive breast carcinomas, mesenchymal 
tumors, male breast tumors, malignant lymphoma, metastatic tumors, precursor lesions, 
benign epithelial lesions, myoepithelial lesions, fibro-epithelial tumors, benign and malignant 
tumors of the nipple. Among which, the invasive ductal carcinoma almost accounts for 55% 
of breast cancer, while invasive lobular carcinoma is rare (5%). Another major type is ductal 
carcinoma in situ (DCIS, 13%) (274), which is characterized by the trait that the surrounding 
tissue is not invaded by cancer cells.  
Receptor status classification is also commonly used as a reference for treatment. For 
example, ER and progesterone receptor (PR) are expressed in some breast cancer cells and 
are considered as prognostic markers (275). Based on the expression of ER and PR, breast 
cancer is diagnosed as ER positive or negative, and PR positive or negative types. Patients 
with ER expression usually receive the treatment of anti-hormone drugs such as Tamoxifen 
and Toremifene (Fareston®) to block the estrogen receptors. In addition, receptor tyrosine-
protein kinase erbB-2 (HER2) or HER2/neu, a member of the human epidermal growth factor 
receptor family, is also an indispensable indicator for patients’ prognosis (275). About 20% 
of breast cancer overexpress HER2 protein commonly via amplification of the gene which 
plays a vital role in initiation and progression of certain aggressive breast cancer types (276). 
This excessive expression of HER2 can be antagonized with drugs that target HER2, such as 
trastuzumab (Herceptin®) and lapatinib (Tykerb®). Triple negative breast cancer (TNBC: 
ER-, PR- and HER2-) is a type with poor prognosis, which is more common in younger 
women with early metastasis. Hormone therapy is invalid for this type since the cancer cells 
lack hormone receptor expression. 
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Molecular subclasses consider tumor histology, receptors status, grade, stage and molecular 
signatures to classify the tumors as subclasses below. The luminal subclass is characterized as 
ER positive, which can be further divided into A, B and ER-/AR+ (androgen receptor) types. 
The name “luminal” originates from the discovery that the gene expression of this pattern is 
most similar to normal luminal cells from the inner side of breast ducts and glands. Luminal 
A type has a better prognosis than B type. The ER-/AR+ type is also termed as “molecular 
apocrine” and the androgen receptor has been reported to be expressed in 12-50% in all ER- 
cases (277). The HER2 subtype has been discussed above. Majority of TNBC belongs to 
basal type with the worst prognosis. In contrast to TNBC, normal like tumors grow slowly 
and show a good prognosis. Their gene expression pattern is mostly similar to normal breast 
epithelial cells.  
A more detailed classification for breast cancer facilitates the discovery of individualized 
treatments. Commonly, gene expression patterns obtained from total RNA have been used to 
identify tumor subgroups in multiple cancers including breast, ovarian, liver, lymphoma and 
soft tissue sarcomas (278-280). These subgroups are considered to reflect cell origin of the 
cancer, a distinct tumor microenvironment and/or other cell biology aspects. Observers’ 
perspective restricts the definition of relevant tumor subtype. If data from total RNA levels 
are adopted as input for identification of subtypes, then only subtypes revealed at this level 
will be observed. Hence, alternative means of studying tumors may identify additional 
clinically relevant entities. Since the hyper-activation of eIF4E in breast cancer and that 
eIF4E affects translation of distinct subsets of genes, it is assumable that mRNA translation 
may provide an alternative perspective on breast cancer subtypes. Considering the vast 
number of RNA binding proteins (>700), it is also possible that non-eIF4E related translation 
is dysregulated in breast cancer. So, only a transcriptome wide approach can conclusively 
answer whether differential translation is manifested in breast cancer in vivo or not. 
1.2.5.4 Therapeutic strategy & Challenge 
The intrinsic diversity of breast cancer requires a multidisciplinary therapeutic strategy. 
Surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, or selective 
combination of several of them is currently used to treat breast cancer in clinic. This is done 
in the adjuvant setting, i.e. after surgery, and the neo-adjuvant setting, i.e. before surgery to 
shrink the tumor’s size and to facilitate excision of the tumor. These treatments lead to side 
effects especially following radiation and chemotherapy due to their low specificity to cancer 
cells.  
1.3 TECHNIQUES TO STUDY TRANSLATION EFFICIENCY 
1.3.1 Polysome profiling 
A well-established technique to study genome wide patterns of mRNA translation is 
polysome-profilng. Polysome-profiling involves immobilization of ribosomes on mRNA by 
employing translation elongation inhibitors (e.g. cycloheximide) followed by isolation of 
efficiently translated mRNA. A cytosolic lysate is first loaded on 5%-50% linear sucrose 
  23 
gradient. Next, during ultracentrifugation, mRNAs sediment according to their association 
with ribosomes which allows for separation of efficiently translated mRNAs (associated with 
>3 complete ribosomes) from inefficiently translated mRNAs (associated with ≤ 3 complete 
ribosomes) (281). Alteration in the distributions of mRNAs over the gradient among different 
conditions can be determined from the mRNA extracted from each fraction. For example, the 
comparison between efficiently translated mRNA from HCT116 p53+/+ in starvation and 
complete medium demonstrated the mRNAs shift across the polysome-profile, as shown in 
Figure 6. For genome wide experiments, mRNA from fractions corresponding to >3 
associated ribosomes are commonly pooled (281). This >3 threshold is used because most 
mRNAs with translational efficiency alteration show a change across this threshold. The 
reason behind this is that the distribution of ribosome association applies to normal 
distribution for both on-off regulation and continuous shifts (152). Moreover, 80% newly 
synthesized polypeptides will be captured by this threshold (282,283). During polysome-
profiling, the efficiently translated mRNAs are commonly obtained by pooling about 10 
fractions corresponding to 5 ml solution collected in 10 Eppendorf tubes. The isolation of 
these mRNAs is done from one fraction to another separately, and the pooling of these 
fractions is during re-suspension of purified RNA pellet. For small samples such as those 
from bio-banked tissues, such extensive dilution may cause sample loss. For larger 
experimental setup, pooling this number of fractions is not only labor intensive and time 
consuming, but also may lead to mistakes of mislabeling samples or erroneous pooling of 
fractions. Therefore, an optimized non-linear sucrose gradient was designed to enrich the 
efficiently translated mRNAs in only 1 or 2 fractions to reduce sample handling 5-10 fold and 
saving time 10-20 fold, which was a successful solution to the aforementioned shortcomings. 
 
Figure 6.  mRNA shifts across the polysome-profilng under starvation via changes in 
translation efficiency. The polysome-profilings of HCT116 p53+/+ under serum starvation and under 
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complete medium are shown in black and red respectively. The black and red dash lines display the 
mRNA shift across polysome-profilling. 
1.3.2 Ribosome profiling 
Ribosome profiling is an emerging tool using deep sequencing of ribosome-protected mRNA 
fragments to determine ribosome positioning in a genome wide pattern (284). An 80S 
ribosome protects around 30 nucleotides from RNase digestion (285,286). Accordingly, such 
ribosome protected fragments (RPFs) can be isolated, sequenced and mapped backwards to 
the original mRNA to pinpoint the location of the ribosome. The mapping of RPFs can help 
to identify translation products by locating translation starting and ending sites, explore 
translation mechanism, such as to find translated upstream open reading frames (uORFs) and 
to identify subsets of ribosomes participating in translation by spotting their physical location 
in cells and monitoring their interacting molecules (284). Although primarily designed to 
study ribosome positioning, translation efficiency can also be assessed by comparing RPFs to 
mRNA levels across conditions. Thus, ribosome profiling annotates the coding regions, 
facilitates the discovery of gene expression regulation underlying diverse biological 
processes, and reveals the key mechanism underlying the protein synthesis, also helps to 
identify unknown proteins (284). 
1.3.3 Comparison between polysome and ribosome profiling 
Because ribosome profiling provides precise position information of ribosome footprints, it 
can be applied to facilitate identification of ribosomal frame shifting, translation initiation at 
non-AUG codons, stop codon readthrough, ribosome pausing and uORF translation 
(284,287-291). However, there are also several disadvantages of ribosome profiling that 
should be considered. Firstly, the translation pausing can cause a signal blurring and an 
experimentally introduced accumulation of ribosomes at a specific location if inhibition is 
slow (284). Secondly, RNA structures or large ribonucleoprotein complexes also lead to 
increased RPFs, which thereby contaminates ribosome footprints and yields false readouts of 
translation (284). Further, short size of ribosome footprints leads to difficulties in determining 
the right alignment position for reads from highly similar or repetitive regions (284). Finally, 
ribosome profiling requires larger mRNA amounts as compared to mRNA-seq (284). 
Applying ribosome profiling to study differential translation has resulted in conflicting results 
as compared to polysome profiling. Hsieh et al. and Thoreen et al. used ribosome-profiling to 
study mTOR-sensitive translation and suggested that mTORC1/EIF4EBP/EIF4E pathway 
exclusively regulates translation of 5’TOP and 5’TOP like mRNAs (163,292). There has 
been a study showing that the translation of TOP mRNAs is independent of 4E-BPs (164). 
This was in stark contrast to a study employing polysome-profiling which suggested that 
mTOR pathway also regulates the translation of non-TOP mRNAs (152). This discrepancy 
was later explained as that ribosome-profiling is more biased towards mRNAs showing large 
shifts in translation efficiency (such as TOP-mRNAs) and less sensitive for detection of 
mRNAs that show intermediate shifts co-occurring with those showing large shifts (152). In 
contrast, polysome profiling shows less bias and can therefore identify differential translation 
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of mRNAs showing large and small shifts in translation efficiency even when these occur 
simultaneously (152). 
1.3.4 Computational methods to analyze translational efficiency 
DNA microarrays and RNA sequencing are used to quantify polysome-associated RNA to 
study regulation of translation from a transcriptome-wide level. To analyze the differential 
expression from quantification of total RNA (293), the large sets of high throughput data 
require specialized computational methods. It is noteworthy that cells’ overall transcription 
level also influences the analysis of the following translation step. Thus in order to study 
translation per se, besides the efficiently translated mRNAs, the cytosolic mRNAs should 
also be measured to counteract the potential effect of cytosolic mRNA levels to differential 
levels of efficiently translated mRNA (294). A lot of previous studies correct the effect of 
cytosolic mRNA level by calculating the log ratio of efficiently translated mRNA levels by 
cytosolic mRNA levels acquired in parallel (295). However, this log ratio method generates a 
great number of biological false positive and negative results (295). Analysis of translational 
activity (Anota) was developed to address these drawbacks (294,295). Anota was initially 
designed to analyze DNA-microarray data but recently, our lab developed anota2seq which 
allows the analysis of data both from ribosome- or polysome-profiling quantified by RNA 
sequencing or DNA-microarray (296). In addition, anota2seq also allows the interrogation of 
a previously unexplored regulation mechanism of gene expression — translational buffering 
which polysome-associated mRNA level maintains the same (as well as protein levels in the 
absence of differential protein degradation) despite alterations of total mRNA level (296). 
Anota2seq was implemented as an R package which was used to analyze the RNA-seq data 
generated from the constituent research in this thesis.  
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis: 
Dysregulated translation is a key factor in tumor biology that contributes to patients’ 
prognosis and guide individualized cancer treatment. This thesis aims to explore the 
possibility that cancer is characterized by differential translation. This would provide some 
clues guiding future therapies targeting faulty translation in cancer. 
The specific aims of the included papers: 
Paper I:  To design an optimized polysome profiling method to enrich efficiently translated 
mRNA in less fractions, validate the yield, reproducibility and general applicability in cell 
lines and small clinical tissues as compared to the standard linear gradient.  
 
Paper II:  To identify changes in mRNA translation downstream of insulin that are 
dependent or independent of mTOR signaling in cells from tissues regarded as insulin 
sensitive or insulin insensitive and transformed or non-transformed cells. To ultimately 
identify effects from insulin that are specific to cancer cells and that are important 
components to their phenotypes. 
 
Paper III:  To elucidate the mechanisms of RITA’s anti-cancer activity, specifically to 
investigate whether this anti-tumor activity is dependent on TP53 and its implication on 
translation through eIF2α phosphorylation. 
 
Paper IV:  To compare the ability of IL-2 and IL-15 to maintain human NK-cell functions 
following cytokine withdrawal to model post-infusion performance. Use the polysome 
profiling to explore the mechanism from a translational perspective and to investigate the role 
of mTOR and STAT-5 pathways in antitumor functions of IL-15 induced NK cell. 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
Polysome-profiling in small tissue samples 
The standard linear gradients of polysome-profiling yield many fractions per sample to 
isolate efficiently translated mRNA, this causes a major limitation by leading to a broad 
dilution of the efficiently translated mRNA, which could lead to a sample loss and technical 
inconstancy, These disadvantages further cause an underestimation of quantification and 
reproducibility of the translatome when performing studies in primary cells or small tissue 
samples. For large study design with over hundreds of samples, this causes laborious work on 
thousands of fractions to pool to get the efficiently translated mRNA.  
3.1.1 The optimized non-linear sucrose gradient reproducibly and consistently isolates 
the efficiently translated mRNA in high quality. 
An optimized non-linear sucrose gradient was invented based on that the number of bound 
ribosomes on the mRNA is associated with their translational efficiency. Moreover, 
ultracentrifugation poses a linear relationship between the log2 number of associated 
ribosomes and sedimentation distance. This facilitates the calculation of the sucrose 
concentration that differentiates mRNAs associated with less than 3 ribosomes from those 
bound with more than 3 ribosomes (efficiently translated mRNA in this scenario). The 
calculation result was 34% (Figure 7A). We set a layer of 55% sucrose at the bottom of 34% 
layer to prevent polysome from further sedimentation and a layer of 5% sucrose above the 
34% sucrose to facilitate sample entry into the gradient. Next, we tried to optimize the 
volumes for each sucrose layers. The objectives are that the optimized gradient should have 
high reproduction and elution time ought to be reduced. We used the BioComp gradient 
maker that is a cylinder to indicate the desired level on tube. The sketch of the optimized 
gradient is shown as in Figure 7B. The pilot experiment of the optimized non-linear gradient 
separated the ribosomal subunits of 40S, 60S and the monosome 80S, following these peaks, 
a high peak appeared between the 34% and 55% sucrose interface. 
The exploration of the fractions around the high peak at the interface of 34% and 55% 
sucrose indicates that the fraction right under the peak and the one after are strongly enriched 
in mRNA with >3 ribosomes while the fraction before the peak, is enriched in mRNA 
associated with <3 ribosomes even though it contains a bit of efficiently translated mRNA. 
We reproducibly observed this pattern in another two independent experiments. This 
optimization collects the efficiently translated RNA in only two fractions. By pooling these 
two fractions and dividing them equally into two parts (one sample and one backup), only 
one tube with efficiently translated mRNA needs to be worked on. 
We assessed the mRNA extracted from human colon cancer cell lines HCT-116 which differ 
in their p53 status (HCT-116p53+/+ and HCT-116p53-/-) after 16h serum-starvation. Serum 
starvation influenced global translation for both cell lines observed as a similar reduction in 
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polysome-associated RNA companied with an enhancement in free ribosome subunits and 
80S. Cytosolic lysates from 6 plates (15 cm) of each cell type was equally divided, each 
equivalent was loaded on the linear gradient and on the optimized non-linear gradient. We did 
four independent experiments. We then extracted mRNA from the linear gradient and the 
optimized non-linear gradient. These two types of gradients produce similar amounts of 
efficiently translated mRNA. And these two gradients both endow persistent isolation of 
essentially intact RNA evaluated by Agilent Bioanalyzer which grades each sample with a 
RNA Integrity Number (RIN).  
 
Figure 7. The sketch of the linear and the optimized non-linear gradients. A. The setup of 5% to 
50% linear sucrose gradient and polysome profiling from the linear gradient. Ultracentrifugation 
separates ribosome subunits of 40S and 60S, monosome 80S and polysomes from cytosolic lysate 
loaded on the linear gradient. (UV signal was captured at the absorbance of 254 nm across the 
sucrose gradient). Efficiently translated mRNA (associated with more than 3 ribosomes) 
corresponding to 34% sucrose concentration is isolated from polysome-fractions. B. The optimized 
non-linear sucrose gradient is composed of 5%, 34% and 55% sucrose layers. This design is to enrich 
mRNA>3 ribosomes at the interface between 34% and 55% sucrose solution. 
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3.1.2 Similar translatomes can be obtained from the optimized non-linear and the 
standard linear sucrose gradient. 
Smart-seq2 (297) with an input of 10 ng RNA was performed to construct cDNA libraries for 
cytosolic RNA and efficiently translated RNA isolated from the optimized non-linear and 
standard linear gradients, also for cytosolic RNA. These RNAs were from HCT-116 cells 
with and without p53 (serum starved for 16h). The principal component analysis of 
sequencing data showed that the first component capturing the main source of variance 
(52.1%) discriminated RNA source between cytosolic mRNA from polysome-associated 
mRNA. The following principal components differentiate samples regarding replicate (16.7% 
of the variance) and p53 status (6.1% of the variance) respectively. This is consistent with 
that results obtained from the two gradients are comparable. We compared gene expression of 
polysome-associated mRNA from the optimized and the linear gradient. When FDR 
threshold was set at 0.1, more differential expression was associated with the optimized 
gradient approach compared to the linear gradient. However, mRNAs identified as 
differentially expressed by the optimized non-linear-gradient covers almost all those 
identified by the linear gradient. Between the two methods, the obtained fold-changes (HCT-
116 p53+/+ vs. p53-/- cells) showed good correlation with spearman coefficient 0.74. And 
lower FDRs were obtained by performing the optimized non-linear gradient. 
3.1.3 Gene expression is affected by P53 status through various mechanisms including 
translational buffering. 
The optimized non-linear sucrose gradient captures more changes in polysome associated 
mRNA, which can be seen from the number of mRNAs showing low FDRs for p53-status 
dependent expression, compared to changes in cytosolic mRNA levels. Correspondingly, 
more mRNAs (682 mRNAs) exhibits regulation in translational efficiency influencing protein 
levels as compared to alteration in mRNA abundance (438 mRNAs). Interestingly, many 
alterations in cytosolic mRNA (373 mRNAs) levels were buffered at the level of mRNA 
translation. Gene Ontology (GO) enrichment analysis demonstrated that mRNAs with mRNA 
abundance pattern in p53+/+ cells were more involved in functions corresponding to 
development, migration and extracellular matrix. Neural related functions were more targeted 
by the genes whose cytosolic mRNA levels were buffered at the level of translation. 
Therefore, it demonstrated selectivity that certain gene expression mechanism targets certain 
cellular functions. 
3.1.4 The performance of optimized non-linear gradients coupled with smartSeq2 on 
breast cancer tissues from bio-bank. 
The optimized non-linear gradient was applied on a cohort of 161 breast cancer tissues to 
isolate their efficiently translated mRNA. The Pearson correlation between RINs of the 
efficiently translated and cytosolic mRNA pools is 0.66. RINs for efficiently translated 
mRNA were higher than RINs in cytosolic input samples, which cleared the suspicion of 
isolation technique that caused a low RIN for the pool of efficiently translated mRNA. We 
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performed RNA sequencing for a set of 5 breast cancer tissues from the cohort. The breast 
cancer translatomes exhibit a high coverage as proven by that an RPKM (Reads per kilobase 
per million mapped read) >0.2 that was obtained by mRNAs from >12 000 genes, and an 
RPKM >1 for >10 000 genes. Hence, the combination of the optimized non-linear gradient 
with RNAseq2 can be used to comprehensively explore the translatomes from bio-banked 
small tissue samples. 
3.2 PAPER II 
Cancer specific effects of insulin on translatomes and metabolomes 
Insulin sensitive mRNA translation has been observed in cancer cells which originates from 
insulin insensitive organs, such as breast. However, whether cancer cells obtain a response 
resembling those observed in cells from insulin-sensitive organs or whether cancer cells tailor 
pathological responses is largely unknown. In addition, how insulin orchestrates effects on 
metabolic program with changes in mRNA translation in cells from insulin sensitive and 
insensitive organs is neither characterized. Hence, this study is to investigate the effects of 
insulin and IGF-1 on selective translation and metabolism in cells from insulin sensitive and 
insensitive organs, coupled with cancer cells originating from an insulin insensitive organ. 
3.2.1 Insulin mediated modulation of mTOR-pathway activity in insulin sensitive and 
insensitive cells 
After 12hs starvation, MCF7 and HMEC/hTERT cells displayed nearly complete lack of 
phosphorylated 4E-BP1 and S6K1. Insulin/IGF1 stimulated such phosphorylation (Fig.8). 
While starved myotubes expressed the phosphorylated 4E-BP1 and S6K1 which was 
enhanced by insulin/IGF1 (Fig.8). In all cell types, torin1 nearly completely abrogated the 
phosphorylation of 4E-BP1 and S6K1 stimulated by insulin/IGF1, for myotubes this level of 
phosphorylation was substantially lower comparing with the starved condition. Therefore, 
insulin/IGF1 regulates activity of the mTOR pathway in cells of insulin sensitive or 
insensitive. 
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Figure 8. Activity of the mTOR pathway is modulated in cells from both insulin sensitive and 
insensitive organs following insulin/IGF1 stimulation. Western blotting using extracts from MCF7, 
HMEC/hTERT and myotubes starved for 12hs followed by stimulation with vehicle or insulin+IGF1 in 
the presence or absence of torin1. Beta-actin was used as a loading control for MCF7 and 
HMEC/hTERT cells while alpha-actin was used for myotubes. 
3.2.2 Selective mTOR dependent modulation of metabolomes in cells from insulin 
sensitive and insensitive organs upon insulin/IGF1 stimulation  
Regarding the metabolomes of myotubes, HMEC/hTERT and MCF7, cells from insulin 
sensitive organs, such as myotubes differ in their insulin/IGF1 and mTOR dependent changes 
as compared to cells from insulin non-sensitive organs, like HMEC/hTERT cells. 
Intriguingly, insulin/IGF1 and mTOR sensitive metabolomes of cancer cells, for example, 
MCF7 cells appear to be different as compared to cells from both insulin sensitive and 
insensitive organs. 
3.2.3 Pervasive modulation of translatomes in cells from both insulin sensitive and 
insensitive organs 
Myotubes displayed abundant changes in both mRNA translation and mRNA abundance 
after insulin/IGF1 treatment. Notably, with mTOR inhibitor torin1, translational buffering 
turned out to be predominant pattern which indicates that the mTOR pathway modulates 
translation of the transcriptional program downstream of insulin/IGF1. In contrast, 
HMEC/hTERT cells showed a prominent buffering pattern independently of whether 
insulin/IGF1 stimulation was performed with or without torin1. At last, insulin/IGF1 
modulated translational efficiencies and to a lesser extent of mRNA abundance and buffering 
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in MCF7 cells. A similar pattern was also discovered with torin1. Hence, cells from insulin 
sensitive and insensitive organs modulate gene expression using different modes. Also, 
mTOR seems to play an important role in deciding which of the mRNAs whose abundance 
changes upon insulin/IGF1 stimulation will be translated. 
3.3 PAPER III 
RITA-induced apoptosis requires eIF2α dependent modulation of mRNA 
translation 
TP53 as a famous tumor suppressor gene is commonly mutated in majority of cancers. Thus 
the reactivation of TP53 by small molecules such as RITA is a promising therapeutic 
strategy. However, how RITA suppresses cell growth and induces apoptosis is still largely 
unknown. This paper explored the mechanism underlying these effects of RITA. 
3.3.1 RITA induces apoptosis and represses mRNA translation by stimulating eIF2α 
phosphorylation, independently of TP53 status, oxidative stress and mTOR pathway. 
1M RITA treatment showed a time-dependent increase in phosphorylation of eIF2α in 
MCF7 cells. eIF2α phosphorylation was also induced by 8hs treatment of 1M RITA in 
colon cancer cell lines GP5d and HCT116 both with wild-type TP53. Integrated stress 
response inhibitor (ISRIB) rescues eIF2B GEF activity independently of the phosphorylation-
state of eIF2α. ISRIB reestablished translation following RITA treatment which was 
confirmed by polysome profiling and quantified by Met-S35 incorporation. So RITA-
suppressed translation is dependent on the phosphorylation of eIF2α. 
8h treatment with 1M RITA in MCF7 cells leads to a strong TP53 accumulation and 
cleavage of the apoptosis marker PARP. RITA reduced the amount of efficient translation 
mRNA two fold with a concomitant increase in 80S monosomes. The assessment of 
dependence between RITA’s effect and TP53 showed that RITA has a similar effect on 
PARP cleavage in MCF7 TP53-/- as compared to MCF7 TP53+/+cells, and the same for the 
proportion of ribosomes engaged in efficient translation. Incorporation of S35-labeled 
methionine in nascent proteins was also measured; this confirmed a similar reduction of 
protein synthesis in TP53+/+ and TP53-/- MCF7 cells upon RITA treatment. Thus, RITA 
induces apoptosis and suppresses global mRNA translation independently of TP53. 
Translation remained suppressed even when RITA-induced reactive oxygen species (ROS) 
accumulation is completely reversed by anti-oxidant NAC. Thus, RITA-associated 
accumulation of ROS does not explain its effects on mRNA translation. Cells lacking 4E-BPs 
showed a similar reduction in the proportion of ribosomes engaged in efficient translation as 
compared to their control cells; no change in phosphorylation of mTOR targets 4E-BP1 or 
S6K was observed following RITA treatment. Thus, RITA modulates translation 
independently of 4E-BPs and the mTOR pathway. 
3.3.2 PERK activity is required for RITA-mediated suppression of mRNA translation. 
  33 
Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibition by inhibitor 
GSK2606414 reduced RITA-induced eIF2α phosphorylation in a dose-dependent manner, 
which rescued RITA-suppressed translation and decreased apoptosis. ER-stress inducer 
thapsigargin but not RITA stimulated a strong phosphorylation of PERK. Thus, RITA does 
not induce ER stress nor activate PERK via phosphorylation at the commonly assessed site 
threonine 980 and it seems that RITA does not appear to induce PERK activity through the 
ER-stress mechanism. 
3.3.3 Modulation of eIF2α phosphorylation largely accounts for RITA’s anticancer 
effects. 
Salubrinal, as an inhibitor of eIF2α phosphatases was used to augment eIF2α 
phosphorylation. 32M salubrinal acted as an enhancer to eIF2α phosphorylation in MCF7 in 
addition to a range of RITA concentrations. Comparing with only RITA treatment, 32µM 
salubrinal with 1µM RITA treatment greatly strengthened induction of apoptosis and 
inhibited colony formation, and 1µM GSK2606414 combined with 1µM RITA leads to an 
increased colony formation as compared to only RITA being used. Therefore, RITA’s 
inductive ability on eIF2 phosphorylation is necessary to efficiently induce apoptosis and 
inhibit colony formation. 
3.4 PAPER IV 
IL-15 activates mTOR and primes stress-activated gene expression leading to 
prolonged antitumor capacity of NK cells 
Activated NK cells by interleukins have been recently used to treat hematological 
malignancies. Nevertheless, the therapeutic effect of activated NK cells is largely reduced by 
the limited post-infusion persistence. In this study, the ability of interleukin-2 and interleukin-
15 to maintain the anti-tumor capability of NK cells was compared by a genome wide 
analysis, the implication of mTOR and STAT-5 signaling was investigated as well. The 
results revealed that mTOR is of importance in regulating metabolic signaling in immune 
cells, and comparing with IL-2, IL-15 showed priority in adoptive NK cell treatment for 
cancer.  
3.4.1 Survival and cytolytic activity is primed by IL-15 in human NK cells. 
A comparable enhancement in primary human NK-cell cytolytic activity and proliferation 
was induced by activated IL-15 or IL-2 at a preset concentration (P<0 .05). While when the 
cytokine concentration is less than 9.15 ng/mL, IL-15 was more capable to retain NK-cell 
proliferation as compared to IL-2. Under cytokine deprivation, NK cells treated by IL-15 
preserved a greater level of cytotoxicity (P<0.05) and underwent a less apoptosis (P <0.05) 
than IL-2-treated NK cells. Retreat IL-15–treated NK cells with IL-15 leaded to higher levels 
of CD251/CD1371–activated NK than IL-2–treated NK cells re-exposed to IL-2. This 
indicates that IL-15 and IL-2 hold the different ability to maintain cytokine signaling and/or 
stimulate the expression of cytokines and/or their corresponding receptors.  
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3.4.2 After cytokine withdrawal, IL-15 and IL-2 differentially regulate steady-state 
levels of mRNA, translational efficiencies in NK cells; IL-15 controls the expression of 
genes involved in mitochondrial function and cell cycle through priming mechanism. 
Before and after cytokine withdrawal, cytosolic and polysome-associated IL-2Rα mRNA 
levels were elevated in NK cells treated with IL-15 as compared to the ones treated with IL-2, 
while CD56 expression was kept mostly unaffected. 
1212 mRNAs exhibited significantly distinct polysome association (FDR<0.15 and fold 
change>1.5) with slight heterogeneity among donors in NK cells treated by IL-15 versus IL-2 
after deprivation of cytokine (573 downregulated genes and 639 upregulated genes), and 
among them, 29% of the genes (350 genes) were translated differentially. GO analysis 
showed selected upregulation of genes involved in cell cycle and mitochondrial functions, 
and it was IL-15 that upregulated majority of mitochondria-related genes. 
Four different groups were identified by the clustering of differentially expressed genes 
spotted under both before and after cytokine deprivation: we found 466 cytokine-primed up-
regulated genes (IL-15 vs IL-2), 286 cytokine-primed down-regulated genes, 173 cytokine-
induced up-regulated genes and 287 cytokine-induced down-regulated genes. Hence, 
intriguingly, IL-15 mainly modulates gene expression in NK cells through cytokine priming 
mode with 62% of all genes. Also, cytokine-primed genes were more inclined to be 
modulated by differential translation as compared to cytokine-induced genes (with 1.7 fold, 
P=0.0002 by fisher exact test).  
The up-regulated genes by cytokine-induced pattern were mainly involved in cell cycle 
functions; Cytokine-induced down-regulated genes primarily participate in cell development, 
motility and cell signaling. Accordingly, genes up-regulated by cytokine-primed pattern were 
more involved in the functions in metabolic processes, respiration and translation; genes 
down-regulated by cytokine-primed pattern mainly took part in cell signaling, transcription 
and developmental progress. Therefore, through cytokine-induced and cytokine-primed 
modes, IL-15 modulates gene expression programs by addressing different cellular functions, 
which is consistent with refined NK-cell activity. 
3.2.3 mTOR, instead of STAT-5, primarily modulates metabolic and cytotoxic functions 
in NK cells activated by IL-15 after cytokine deprivation; and IL-15-stimulated NK 
cells are resistant to cytokine deprivation. 
IL-15 induced elevated phosphorylation of S6K which is a substrate of mTOR. Even after 24 
hours of cytokine deprivation, comparing with IL-2, IL-15 stimulated S6K phosphorylation 
was still maintained at a minor level. 
IL-15-treated NK cells exhibited a higher capability in basal and maximal cellular respiration 
as compared to the ones treated with IL-2. Torin-1 treatment deleted a series of biological 
effects of NK cells induced by IL-15. For example, Torin-1 diminished the S6K 
phosphorylation associated with IL-15 before and after cytokine deprivation, it also 
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weakened IL-15 induced respiratory activity (P<0.05). Hence, amplified mTOR activity is of 
independency for refined cytotoxic and metabolic activities of IL-15-treated NK cells after 
cytokine deprivation. In addition, STAT-5 plus mTOR inhibition decreased the cytolytic 
functions of NK cells activated by IL-15 at all effector-to-target ratios (P<0.05). Prominently, 
concurrent suppression of mTOR and STAT-5 did not affect NK cells’ cytolytic function 
after cytokine deprivation as compared to using torin-1 only, revealing that prolonged NK-
cell activation primed by IL-15 is STAT-5 independent but mTOR dependent. Even though 
STAT-5 influences some phenotypes of IL-15–activated NK-cell, after cytokine deprivation, 
metabolic and cytotoxic functions are primarily dependent on mTOR instead of STAT-5 
signaling. 
A clinically approved protocol was used to assess the functionality of NK cells induced by 
IL-15. NK cells expanded with IL-15 leaded to a higher expression of CD25 than IL-2. After 
cytokine deprivation, CD25 expression and certain other activating receptors such as, NKp30, 
NKp44, CD69, NKG2D and CXCR3 maintained increased on NK cells expanded by IL-15 
as compared to IL-2–expanded NK cells. 
3.2.4 The expression of IL-15 predicates a better clinical prognosis in B-cell lymphoma 
patients. 
We reanalyzed a pre-published mRNA dataset obtained from tissue samples of B-cell 
lymphoma patients. We plotted the residuals of a blank Cox model against IL-15 expression 
to investigate the influence of IL-15 expression on prognosis. The results indicated a poor 
prognosis for patients with low expression of IL-15. 
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4 CONCLUSION 
Paper I: Polysome-profiling in small tissue samples  
The optimized non-linear sucrose gradient collects and enriches the efficiently translated 
mRNA (>3 ribosomes associated) in merely one or two fractions. The sample handling was 
largely reduced by 5-10 fold and time was saved for RNA extraction by 10-20 fold. By 
combining with Smart-seq2, which is developed for single-cells cDNA library construction, 
this optimized polysome profiling provides the possibility to produce data on translatomes 
from bio-banked or clinical small tissue samples and from low amount of cells. Notably, this 
method yields very similar data on translatomes as compared to the standard linear gradient 
method. Therefore, polysome profiling can be performed on RNA-amount-limited small 
tissues samples or primary cells. 
Paper II: Cancer specific effects of insulin on translatomes and metabolomes 
The metabolomes of myotubes and HMEC/hTERT cells were modulated by insulin/IGF1 in 
an mTOR dependent manner, but their metabolic pathways affected were different. 
Intriguingly, MCF7 cells tailored their metabolic response to insulin/IGF1 stimulation. Upon 
insulin/IGF1 stimulation, HMEC/hTERT, myotubes and MCF7 cells displayed distinct 
changes in mRNA abundance, translation and translational buffering. So, MCF7 has 
programmed pathological responses to insulin stimulation, which differs from those 
discovered in insulin sensitive or insensitive cells.  
Paper III: RITA-induced apoptosis requires eIF2α dependent modulation of mRNA 
translation 
RITA induces apoptosis and represses mRNA translation by inducing eIF2α phosphorylation 
independently of TP53 status and the mTOR pathway. Suppression of eIF2α phosphorylation 
by inhibition of the upstream kinase PERK rescues mRNA translation with a concomitant 
reversal of RITA’s effects on apoptosis and clonogenicity. Correspondingly, RITA’s anti-
cancer activity can be enhanced by inhibiting dephosphorylation of eIF2α. Hence, modulation 
of mRNA translation via phosphorylation of eIF2α is required for RITA’s anti-cancer 
properties. 
Paper IV: IL-15 activates mTOR and primes stress-activated gene-expression leading to 
prolonged antitumor capacity of NK cells 
The studies in this paper prompt the understanding of the establishment and maintenance of 
cytokine-activated NK cells; the paper also reveals the significance of mTOR-mediated 
metabolic and cytotoxic effects of immune cells by examining the cytokine-mediated gene 
expression programs and downstream cellular functions of NK cells. The paper argues for the 
application of IL-15 for adoptive NK-cell therapy, and the research on NK cells also 
enlightens scientists to perform similar studies on other immune cells. 
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为哄我入睡，你们给我翻录并播放的《妈妈的吻》，到在我生病时，日夜陪伴在我身
边体贴入微的照顾和守护，儿都铭刻在心。如今儿子圆满地完成了博士学业，希望今
后能利用自己学到的知识，服务于社会，实现个人的理想和价值。回报和照顾你们，
能够让你们颐享天年。我爱你们！祝愿你们健康，长寿，心情舒畅，平安如意！ 
致亲戚 (To my relatives)  
首先感谢爷爷奶奶，姥爷姥姥，感谢你们对儿时的我的悉心照料。虽然儿时的很多记
忆已经模糊了，但爷爷抱起我，亲我时的胡渣，奶奶熬得葡萄干稀饭，姥爷对我儿时
的教育以及做的疙瘩汤，以及姥姥给我哼唱的大吊车，带我在准格尔大厦门口吃烤肉
凉面的场景将永远存留在我儿时的记忆中。感谢大伯和小姑一家当我在爷爷奶奶家时
的陪伴。感谢大舅，小姨和小舅一家对我的关心和照顾。感谢梁燕姐姐，姐夫，郭婷
妹妹，妹夫，乐乐弟弟，丹丹妹妹，超超妹妹的陪伴和支持。有了你们大家，我在家
乡的生活才有了亲情的陪伴和家的温暖，我爱你们！ 
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